Achaogen antibiotic headed toward submissions

Achaogen Inc. (NASDAQ:AKAO) rocketed $7.78 (148%) to $13.03 on Monday after reporting that its lead candidate plazomicin (ACHN-490) met FDA’s and EMA’s primary endpoints in the Phase III EPIC trial in

Read the full 310 word article

User Sign In